GGrantIndex
← Leaderboards

Rosalind Ramsey-Goldman

Northwestern University

Google Scholar ↗PubMed ↗ORCID ↗
$7,639,224
Attributed
$11,150,061
Total exposure
35
Grants
18
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.6M · FY2005–24
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$11,150,061 · 35

By mechanism

R01$5,282,271 · 2
P60$1,949,474 · 2
R21$1,196,370 · 3
K24$1,023,409 · 1
U34$732,902 · 1
M01$513,513 · 23

Top collaborators

Most similar at Northwestern University

Same institution · by research overlap

Others in their field

Top investigators on “Systemic Lupus Erythematosus”

Research focus

Systemic Lupus ErythematosusClinical ResearchHuman SubjectBone DensityChronicLupusOsteoporosisAfrican AmericanAffectFemaleInflammationProgramsDisease /Disorder Proneness /RiskLongitudinal Human StudyAutoimmune DiseasesPlayCardiovascular DiseasesMeasurementPersonsQuality Of LifeCaucasian AmericanDesignIndexingRacial /Ethnic Difference

Grant awards (72)

Leveraging Community-Academic Partnerships and Social Networks to Disseminate Vaccine-Related Information and Increase Vaccine Uptake Among Black Individuals with Rheumatic Diseases$709,413
R01 · FY2024 · AR · contact PI
Leveraging Community-Academic Partnerships and Social Networks to Disseminate Vaccine-Related Information and Increase Vaccine Uptake Among Black Individuals with Rheumatic Diseases$738,723
R01 · FY2023 · AR · contact PI
Differentiating clinical characteristics between two subtypes of antiphosphatidylethanolamine$200,000
R21 · FY2023 · AI
Leveraging Community-Academic Partnerships and Social Networks to Disseminate Vaccine-Related Information and Increase Vaccine Uptake Among Black Individuals with Rheumatic Diseases$791,024
R01 · FY2022 · AR · contact PI
Lupus Intervention Fatigue Trial (LIFT)$554,877
R01 · FY2022 · AR · contact PI
Differentiating clinical characteristics between two subtypes of antiphosphatidylethanolamine$240,000
R21 · FY2022 · AI
Lupus Intervention Fatigue Trial (LIFT)$606,357
R01 · FY2021 · AR · contact PI
Lupus Intervention Fatigue Trial (LIFT)$770,161
R01 · FY2020 · AR · contact PI
Lupus Intervention Fatigue Trial (LIFT)$646,503
R01 · FY2019 · AR · contact PI
Lupus Intervention Fatigue Trial (LIFT)$120,925
R01 · FY2019 · AR · contact PI
Lupus Intervention Fatigue Trial (LIFT)$344,288
R01 · FY2018 · AR · contact PI
Algorithms to Identify Systemic Lupus from Electronic Health Record Data$173,800
R21 · FY2018 · AR · contact PI
Algorithms to Identify Systemic Lupus from Electronic Health Record Data$208,395
R21 · FY2017 · AR · contact PI
Planning Activity and Nutrition Trial in Lupus to Energize and Renew$367,777
U34 · FY2015 · AR · contact PI
Planning Activity and Nutrition Trial in Lupus to Energize and Renew$365,125
U34 · FY2014 · AR · contact PI
Cancer Risk: Advancing knowledge in systemic rheumatic disease$68,062
R03 · FY2014 · CA
Cancer risk after renal transplant in autoimmune disease$73,518
R03 · FY2013 · CA · contact PI
Cancer Risk: Advancing knowledge in systemic rheumatic disease$70,167
R03 · FY2013 · CA
Fatigue and Lifestyle Physical Activity in SLE$171,698
R21 · FY2012 · AR · contact PI
Cancer risk after renal transplant in autoimmune disease$91,875
R03 · FY2012 · CA · contact PI
Study of Lupus Vascular and Bone Longterm Endpoints$382,958
P60 · FY2011 · AR · contact PI
Fatigue and Lifestyle Physical Activity in SLE$202,477
R21 · FY2011 · AR · contact PI
Study of Lupus Vascular and Bone Longterm Endpoints$339,295
P60 · FY2010 · AR · contact PI
Study of Lupus Vascular and Bone Longterm Endpoints$299,192
P60 · FY2009 · AR · contact PI
Patient Oriented Research: Systemic Lupus Erythematosus$93,887
K24 · FY2009 · AR · contact PI
Study of Lupus Vascular and Bone Longterm Endpoints$290,177
P60 · FY2008 · AR · contact PI
Patient Oriented Research: Systemic Lupus Erythematosus$91,938
K24 · FY2008 · AR · contact PI
Study of Lupus Vascular and Bone Longterm Endpoints$289,534
P60 · FY2007 · AR · contact PI
Patient Oriented Research: Systemic Lupus Erythematosus$90,045
K24 · FY2007 · AR · contact PI
LONG TERM CONSEQUENCES OF SLE: VASCULAR AND BONE COMPLICATIONS$51,639
M01 · FY2007 · RR · contact PI
A GENETIC RISK PROFILE IN LONGITUDINAL SYSTEMIC LUPUS ERYTHEMATOSES COHORTS$30,160
M01 · FY2007 · RR · contact PI
EPIDEMIOLOGY OF OSTEOPOROSIS IN WOMEN WITH LUPUS - MAMDC PROJECT$3,198
M01 · FY2007 · RR · contact PI
TRANSESOPHAGEAL ECHOCARDIOGRAPHY EVALUATION AND MRI OF THE AORTA IN LUPUS$1,371
M01 · FY2007 · RR · contact PI
PREDICTORS OF PREGNANCY OUTCOMES IN SLE AND APS$914
M01 · FY2007 · RR · contact PI
Patient Oriented Research: Systemic Lupus Erythematosus$88,208
K24 · FY2006 · AR · contact PI
LONG TERM CONSEQUENCES OF SLE: VASCULAR AND BONE COMPLICATIONS$52,371
M01 · FY2006 · RR · contact PI
A GENETIC RISK PROFILE IN LONGITUDINAL SYSTEMIC LUPUS ERYTHEMATOSES COHORTS$48,148
M01 · FY2006 · RR · contact PI
EPIDEMIOLOGY OF OSTEOPOROSIS IN WOMEN WITH LUPUS - MAMDC PROJECT$12,249
M01 · FY2006 · RR · contact PI
REVISING ACR DIAGNOSTIC/CLASSIFICATION CRITERIA FOR LUPUS$11,825
M01 · FY2006 · RR · contact PI
PREDICTORS OF PREGNANCY OUTCOMES IN SLE AND APS$422
M01 · FY2006 · RR · contact PI
Patient Oriented Research: Systemic Lupus Erythematosus$86,486
K24 · FY2005 · AR
Exposure to Immunosuppressive Drugs &Cancer Risk in SLE$74,250
R03 · FY2005 · CA
A GENETIC RISK PROFILE IN LONGITUDINAL SYSTEMIC LUPUS ERYTHEMATOSES COHORTS$58,480
M01 · FY2005 · RR
LONG TERM CONSEQUENCES OF SLE: VASCULAR AND BONE COMPLICATIONS$27,169
M01 · FY2005 · RR
EPIDEMIOLOGY OF OSTEOPOROSIS IN WOMEN WITH LUPUS - MAMDC PROJECT$22,103
M01 · FY2005 · RR
PATIENT-ORIENTED RESEARCH: SYSTEMIC LUPUS ERYTHEMATOSUS$116,361
K24 · FY2004 · AR
Exposure to Immunosuppressive Drugs &Cancer Risk in SLE$74,250
R03 · FY2004 · CA
A Genetic Risk Profile in Longitudinal Systemic Lupus Erythematoses Cohorts$37,088
M01 · FY2004 · RR
Epidemiology of Osteoporosis in Women with Lupus - MAMDC Project$28,630
M01 · FY2004 · RR
Long Term Consequences of SLE: Vascular and Bone Complications$24,726
M01 · FY2004 · RR
The Risk of Osteoporosis in Patients with Recent Onset SLE$650
M01 · FY2004 · RR
PATIENT-ORIENTED RESEARCH: SYSTEMIC LUPUS ERYTHEMATOSUS$116,319
K24 · FY2003 · AR
PATIENT-ORIENTED RESEARCH: SYSTEMIC LUPUS ERYTHEMATOSUS$115,946
K24 · FY2002 · AR
Longterm consequences of Lupus;vascular and bone complications$0
P60 · FY2002 · AR
EPIDEMIOLOGY OF OSTEOPOROSIS IN WOMEN WITH LUPUS$174,159
P60 · FY2001 · AR
PATIENT-ORIENTED RESEARCH: SYSTEMIC LUPUS ERYTHEMATOSUS$113,347
K24 · FY2001 · AR
Genetic risk profile in longitudinal systemic lupus erythematoses$0
M01 · FY2001 · RR
RISK OF OSTEOPOROSIS IN PATIENTS WITH RECENT ONSET SYSTEMIC LUPUS ERYTHMATOSUS$0
M01 · FY2001 · RR
TRIAL OF REPEATED DOSES OF LJP 394 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHMATOSUS$0
M01 · FY2001 · RR
EPIDEMIOLOGY OF OSTEOPOROSIS IN WOMEN WITH LUPUS - Arthritis Foundation Project$0
M01 · FY2001 · RR
GL9501--LONG TERM SAFETY AND TOLERABILITY OF GL701 IN PATIENTS WITH SLE$0
M01 · FY2001 · RR
EPIDEMIOLOGY OF OSTEOPOROSIS IN WOMEN WITH LUPUS - MAMDC Project$0
M01 · FY2001 · RR
EPIDEMIOLOGY OF OSTEOPOROSIS IN WOMEN WITH LUPUS$174,159
P60 · FY2000 · AR
PATIENT-ORIENTED RESEARCH: SYSTEMIC LUPUS ERYTHEMATOSUS$110,872
K24 · FY2000 · AR
GL95-02--GL701 IN FEMALE PATIENTS WITH ACTIVE SLE$20,474
M01 · FY2000 · RR
GL9501--LONG TERM SAFETY AND TOLERABILITY OF GL701 IN PATIENTS WITH SLE$20,474
M01 · FY2000 · RR
EPIDEMIOLOGY OF REPRODUCTIVE OUTCOME IN LUPUS$20,474
M01 · FY2000 · RR
RISK OF OSTEOPOROSIS IN PATIENTS WITH RECENT ONSET SYSTEMIC LUPUS ERYTHMATOSUS$20,474
M01 · FY2000 · RR
TRIAL OF REPEATED DOSES OF LJP 394 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHMATOSUS$20,474
M01 · FY2000 · RR
EPIDEMIOLOGY OF OSTEOPOROSIS IN WOMEN WITH LUPUS - Arthritis Foundation Project$0
M01 · FY2000 · RR
EPIDEMIOLOGY OF OSTEOPOROSIS IN WOMEN WITH LUPUS - MAMDC Project$0
M01 · FY2000 · RR
Genetic risk profile in longitudinal systemic lupus erythematoses$0
M01 · FY2000 · RR